Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Achillion Pharmaceuticals
Biotech
Alexion dumps ex-Achillion C3G program after seeing phase 2 data
The move follows a “suboptimal” clinical response in two phase 2 trials in C3 glomerulopathy patients that were expected to support regulatory talks.
Nick Paul Taylor
Jul 30, 2020 8:15am
Ex-Achillion nephrology lead jumps ship to Gemini
May 8, 2020 8:25am
Alexion inks deal to acquire Achillion for $930M upfront
Oct 16, 2019 8:22am
Enzyvant finds new CEO in former Alexion exec—Chutes & Ladders
Feb 22, 2019 9:00am
Chutes & Ladders—Novartis brings in CEO to clean up Korean wing
Aug 24, 2018 9:50am
Achillion lures Zelenkofske from uniQure to fill CMO seat
Aug 21, 2018 8:37am
